Acute myeloid leukaemia after treatment with (90)Y-ibritumomab tiuxetan for follicular lymphoma

Hematol Oncol. 2008 Sep;26(3):179-81. doi: 10.1002/hon.849.

Abstract

We report here a patient with relapsed follicular lymphoma who developed secondary acute myeloid leukaemia 15 months after radioimmunotherapy (RIT) with (90)Y-ibritumomab tiuxetan, the fifth described case to date. We review the literature for the potential causal relationship between RIT and secondary myelodysplastic syndromes/acute myeloid leukaemia.

Publication types

  • Case Reports

MeSH terms

  • Antibodies, Monoclonal / therapeutic use*
  • Female
  • Humans
  • Leukemia, Myeloid, Acute / etiology*
  • Lymphoma, Follicular / radiotherapy*
  • Middle Aged
  • Neoplasms, Second Primary / etiology*
  • Radioimmunotherapy*
  • Yttrium Radioisotopes / therapeutic use*

Substances

  • Antibodies, Monoclonal
  • Yttrium Radioisotopes
  • ibritumomab tiuxetan